---
title: "Clinical research organizations: Industry Risk Guide"
description: "Clinical research organizations run drug, device and vaccine trials for sponsors: recruiting volunteers and patients, dosing them in their own units or at…"
url: https://www.urbanstat.com/industry-risk-guides/clinical-research-organizations/
type: Industry risk guide: UrbanStat’s underwriting guide for one business type
publisher: UrbanStat
---

# Clinical research organizations

Clinical research organizations run drug, device and vaccine trials for sponsors: recruiting volunteers and patients, dosing them in their own units or at partner sites, monitoring safety and managing trial data. The exposure is people given unproven treatments, sponsor contracts that shift liability, and a large store of sensitive health data.

Professional, Scientific, and Technical Services · NAICS 541715 · SIC 8731 · Updated November 2026

Risk profile

1. [Property Elevated](#line-property)
2. [Business interruption Elevated](#line-bi)
3. [Premises liability Elevated](#line-gl)
4. [Products and completed work Elevated](#line-products)
5. [Workers’ injury Moderate](#line-wc)
6. [Commercial auto Moderate](#line-auto)
7. [Crime and theft Elevated](#line-crime)
8. [Inland marine and equipment Elevated](#line-marine)
9. [Environmental Moderate](#line-env)
10. [Cyber and data High](#line-cyber)
11. [Professional liability Severe](#line-prof)
12. [Umbrella and excess High](#line-umbrella)

**Professional liability.** Dosing errors, missed safety signals, consent failures and data errors can injure subjects or cost a sponsor its approval timeline.

Loss drivers

## Where losses come from.

1. Volunteers and patients harmed by investigational drugs, devices or dosing errors during a trial
2. Consent, eligibility or protocol failures that injure subjects or void a sponsor's data
3. Breaches and outages of trial databases holding health records and unblinded results

How it compares Each line’s rating against the average for its NAICS sector, Professional, Scientific, and Technical Services (38 business types), and for all 747.

- Clinical research organizations
- Sector average
- All business types

**Low** **Moderate** **Elevated** **High** **Severe**

1. Property Property Property: Elevated, 3 of 5; sector average 1.6; all business types 2.9.
2. Business interruption Interruption Business interruption: Elevated, 3 of 5; sector average 2.0; all business types 2.7.
3. Premises liability Premises Premises liability: Elevated, 3 of 5; sector average 2.2; all business types 2.7.
4. Products and completed work Products Products and completed work: Elevated, 3 of 5; sector average 1.7; all business types 2.6.
5. Workers’ injury Workers Workers’ injury: Moderate, 2 of 5; sector average 2.0; all business types 3.0.
6. Commercial auto Auto Commercial auto: Moderate, 2 of 5; sector average 2.1; all business types 2.5.
7. Crime and theft Crime Crime and theft: Elevated, 3 of 5; sector average 2.1; all business types 2.2.
8. Inland marine and equipment Marine Inland marine and equipment: Elevated, 3 of 5; sector average 2.4; all business types 2.6.
9. Environmental Environmental Environmental: Moderate, 2 of 5; sector average 1.5; all business types 2.3.
10. Cyber and data Cyber Cyber and data: High, 4 of 5; sector average 3.1; all business types 2.7.
11. Professional liability Professional Professional liability: Severe, 5 of 5; sector average 3.4; all business types 2.0.
12. Umbrella and excess Umbrella Umbrella and excess: High, 4 of 5; sector average 2.8; all business types 3.6.

What’s changing

- Decentralized trials send nurses, devices and study drug to subjects' homes, adding driving, home-visit and courier exposure while shrinking time in the clinic.
- Wearables, apps and remote consent collect more subject data from more places, widening breach and privacy exposure across regions with differing rules.
- Cell, gene and other advanced therapies push more first-in-human and high-risk dosing into CRO units, raising the severity of a single adverse event.

Line by line

## Twelve lines, rated.

Each line shows its rating and the reason for it; open a line for what to watch for and the controls that matter. Ratings are UrbanStat’s own editorial view of a typical business of this type, on a five-step scale. They are a starting point for questions, not a quote, a rate or a statistical measure.

### Property: Elevated (3 of 5)

Offices carry little hazard, but clinical units, bioanalytical labs and sample freezers hold costly, irreplaceable material sensitive to smoke, water and power loss.

Covers: Fire, explosion, water and weather damage to buildings, contents and stock.

**Watch for**

- Ultra-low freezers holding trial samples with no alarm or backup unit
- Labs using solvents, dry ice and compressed gases beside clinical areas
- Study drug kept in one pharmacy room with no temperature backup

**Controls that matter**

- Freezer alarms monitored around the clock with spare capacity on standby
- Standby generator covering freezers, drug refrigerators and data rooms
- Labs separated from clinical and office areas by fire-rated walls

### Business interruption: Elevated (3 of 5)

A lost clinical unit or sample store halts enrolled studies, and sponsors move work elsewhere rather than wait for a rebuild.

Covers: How long and how costly a shutdown is.

**Watch for**

- One clinical pharmacology unit earning most of the revenue
- Milestone-based contracts where payment stops when a study pauses

**Controls that matter**

- Agreements with partner sites to take over enrolled studies
- Duplicate sample sets split between two storage locations

### Premises liability: Elevated (3 of 5)

Healthy volunteers live in phase I units for days, and patients visit for dosing and blood draws, then faint, fall or need emergency transfer.

Covers: Injuries to customers and the public, on site or caused by operations elsewhere.

**Watch for**

- Overnight units with shared rooms, showers and recreation areas
- Paid volunteers who conceal health conditions or drug use
- Volunteers and visitors moving through buildings shared with labs

**Controls that matter**

- Fall-risk checks and bed alarms in the hours after dosing
- Escorted access and supervised common areas in residential units

### Products and completed work: Elevated (3 of 5)

Subjects harmed by a sponsor's investigational product sue everyone in the chain, and CROs that pack, label or ship trial supplies share the blame.

Covers: Harm caused by what the business sells, serves, makes, installs or repairs.

**Watch for**

- Clinical supply packaging, blinding and labeling done in house
- Sponsor indemnities that are missing, capped or from thinly funded start-ups

**Controls that matter**

- Written sponsor indemnity and proof of the sponsor's trial insurance
- Second-person checks on kit labels, randomization codes and expiry dates

### Workers’ injury: Moderate (2 of 5)

Most staff are monitors, data managers and statisticians; clinic and lab staff face needlesticks, potent compounds, dry ice and lifting.

Covers: Injuries and illness to employees.

**Watch for**

- Monitors traveling constantly between sites, often by long drives
- Clinic staff handling potent or cytotoxic investigational products

**Controls that matter**

- Safety-engineered needles and sharps disposal at every draw station
- Closed handling and protective gear for potent compounds

### Commercial auto: Moderate (2 of 5)

Monitors drive rented and personal cars to trial sites, and some units shuttle volunteers or send nurses on home visits.

Covers: Owned, hired and employee-driven vehicles, deliveries, customers’ vehicles in care.

**Watch for**

- Volunteer shuttles or home-visit nursing in company vehicles
- Samples carried by staff rather than specialist couriers

**Controls that matter**

- Hired and non-owned auto cover with driving record checks
- Specialist couriers for samples and investigational product

### Crime and theft: Elevated (3 of 5)

Large pass-through payments to investigator sites, volunteer stipends and controlled study drugs invite payment fraud, fictitious subjects and diversion.

Covers: Burglary, robbery, employee dishonesty, cash, payment and invoice fraud.

**Watch for**

- Changes to site payment details requested by email
- Controlled substances under study with weak dispensing records
- Volunteer stipends loaded onto prepaid cards by unsupervised staff

**Controls that matter**

- Callback checks on every change of site or vendor bank details
- Double-locked drug storage with dispensing reconciled to dosing records

### Inland marine and equipment: Elevated (3 of 5)

Study drug, temperature-controlled samples and loaned equipment move constantly between sponsors, sites, labs and depots.

Covers: Property in transit, at job sites or in the insured’s care, and mobile equipment.

**Watch for**

- Samples shipped across borders on dry ice or liquid nitrogen
- Sponsor-owned drug and devices held with unclear custody terms

**Controls that matter**

- Temperature loggers on every shipment with excursion procedures
- Contracts stating who bears loss of sponsor property in the CRO's care

### Environmental: Moderate (2 of 5)

Medical waste, sharps, lab solvents and returned study drug need licensed disposal; radiolabeled studies add a small radioactive stream.

Covers: Pollution on or from the site or the work.

**Watch for**

- Unused study drug returned from sites and stored awaiting destruction
- Radiolabeled or cytotoxic compounds used in clinic or lab

**Controls that matter**

- Licensed medical and chemical waste contractors issuing destruction certificates

### Cyber and data: High (4 of 5)

Trial data systems and safety databases hold patients' health records and sponsors' unblinded results, and an outage stops trials in many regions.

Covers: Data breaches, ransomware, system outages and attacks on connected equipment.

**Watch for**

- Trial systems open to many outside sites, sponsors and vendors
- Older validated systems left unpatched to avoid revalidation
- Subjects' health records held across regions with differing privacy rules

**Controls that matter**

- Multi-factor access and prompt removal of departed site users
- Tested restores of trial databases from offline backups
- Patching and revalidation plan agreed with sponsors in advance

### Professional liability: Severe (5 of 5)

Dosing errors, missed safety signals, consent failures and data errors can injure subjects or cost a sponsor its approval timeline.

Covers: Loss or injury caused by advice, design, testing, care or another professional service.

**Watch for**

- First-in-human and high-risk dosing studies in the CRO's own unit
- Sponsor contracts making the CRO liable for delays or rejected data
- Investigators and nurses whose licenses and training go unverified

**Controls that matter**

- Independent safety review and staggered dosing in early-phase studies
- Liability caps tied to fees, with sponsor indemnity for product harm
- Audit trails, quality reviews and deviation tracking on every study

### Umbrella and excess: High (4 of 5)

A severe reaction in a first-in-human cohort can leave several healthy volunteers critically injured at once, far beyond primary limits.

Covers: How likely one liability event is to exhaust primary limits.

**Watch for**

- Early-phase units dosing several volunteers on the same day
- Sponsors with thin balance sheets and low trial insurance limits

**Controls that matter**

- Sentinel dosing with a waiting period before the rest of the cohort
- Proof of adequate sponsor limits before each study starts

Property picture

## Construction, occupancy, protection, exposure.

What a risk engineer expects to find at a typical site of this type, and what to compare a submission against.

- **Construction**: Modern office buildings or business-park units, often with a fitted-out clinical unit, bioanalytical lab and sample store in the same building as offices.
- **Occupancy**: Clinical wards with beds, medical gases and pharmacy rooms; labs with solvents, dry ice and liquid nitrogen; banks of ultra-low freezers running around the clock.
- **Protection**: Full sprinklers, labs in separate fire areas, monitored freezer and temperature alarms, a standby generator for clinical and cold storage, and controlled access to dosing areas.
- **Exposure**: Units often sit near hospitals or in mixed business parks; a neighbor's fire or a utility outage threatens freezers and dosed volunteers who cannot simply leave.

Checklist

## What to ask and look for.

Start with the desk review before quoting, then walk the site. Tick questions off as you go; ticks are kept in this browser only.

### Before quoting: ask the broker or owner

- What is the mix of early-phase, late-phase, device, lab, data and site management work?
- Does the CRO dose subjects in its own units, and does it run first-in-human or pediatric studies?
- In which regions do studies run, and are any investigator sites owned or managed by the CRO?
- How do sponsor contracts allocate indemnity, liability caps and responsibility for subject injury?
- What trial insurance do sponsors carry, and are any of them small companies without revenue?
- What audit findings, serious adverse events or sponsor disputes have arisen in the last five years?

### Documents to request

- Loss runs for the current and prior policy terms
- Master services agreement used with sponsors
- List of active studies by phase, region and enrolled subjects
- Recent regulatory inspection and sponsor audit reports
- Procedures for informed consent and adverse event reporting

### On site: clinical unit

- How are volunteers screened for health conditions, drug use and enrollment in other trials?
- Who is on site overnight, and how quickly can a subject reach emergency care?
- Where are resuscitation equipment and emergency drugs kept, and when were they last checked?
- How is consent taken, recorded and repeated when a protocol changes?

### On site: pharmacy, labs and samples

- How is investigational product received, stored, dispensed and reconciled?
- What alarms and backup capacity protect freezers and drug refrigerators?
- Which hazardous materials are used in the labs, and how is waste removed?

### On site: data and systems

- Which systems hold subject data, and who outside the CRO can log in?
- How often are trial databases backed up, and when was a restore last tested?

### On site: people and quality

- How are investigators' and nurses' licenses and training checked and kept current?
- How are protocol deviations and serious adverse events tracked to closure?
- How are staff trained on a new protocol or amendment before the next subject is dosed?

### Refer or decline if you find

- First-in-human studies with no sentinel dosing or on-site emergency cover
- Sponsor contracts with no indemnity for injuries caused by the product
- Freezers holding trial samples with no remote alarm or backup power
- Repeated inspection findings on consent, eligibility or data integrity
- Subjects enrolled at sites whose investigators were never vetted

Location

## How UrbanStat data helps.

Sample freezers, drug refrigerators and dosed volunteers depend on steady power. Floods, hurricanes and earthquakes that cut utilities for days threaten irreplaceable samples and force evacuation of residential units.

Flood · Hurricane · Earthquake · Wind

- Flood and hurricane scores at the address show whether freezer rooms and drug stores on lower floors are exposed, before pricing spoilage and interruption cover.
- Live event overlays during a hurricane or wildfire show which clinical units and sample stores sit in the path, while there is still time to move samples.
- Street-by-street exposure views show insured values clustering where several labs and clinical units share a research park, with alerts when a set threshold is passed.

[Request a Demo →](https://www.urbanstat.com/demo/) · [Risk Selection](https://www.urbanstat.com/products/risk-selection/)

Flood · Hurricane · Earthquake · Wind

Public loss data

## What the published numbers say.

Official statistics for the industry or property type closest to this business. They describe the industry as a whole, not any one insured.

Workers’ injury frequency

**0.6** recordable injuries and illnesses per 100 full-time workers, below the private-industry average of 2.3.

Scientific research and development services

**0.6**

All private industry

**2.3**

0.1 of these cases per 100 workers involved days away from work.

United States, 2024. Industry: Scientific research and development services (NAICS 5417), the closest published group. Source: [U.S. Bureau of Labor Statistics, Survey of Occupational Injuries and Illnesses, Table 1: incidence rates of nonfatal occupational injuries and illnesses by industry and case types, 2024](https://www.bls.gov/web/osh/table-1-industry-rates-national.htm).

Workplace deaths

**65** fatal work injuries in 2024, most often from transportation incidents (23).

United States, private industry, 2024. Industry: Professional, Scientific, and Technical Services (NAICS 541), the closest published group. Source: [U.S. Bureau of Labor Statistics, Census of Fatal Occupational Injuries](https://www.bls.gov/iif/fatal-injuries-tables/fatal-occupational-injuries-table-a-1-2024.htm).

Most cited safety standards

**34** citations from 13 inspections; 74% were classed serious, willful or repeat.

- 1910.147 The control of hazardous energy (lockout/tagout) **5**
- 1910.1450 Occupational exposure to hazardous chemicals in laboratories **4**
- 1910.212 General requirements for all machines **2**
- 1910.141 Sanitation **2**
- 1910.157 Portable fire extinguishers **2**

Standards cited most often in this industry, by number of citations.

United States, citations issued October 2024 to September 2025 (federal fiscal year 2025). Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715). Covers federal and state-plan inspections. A citation is one violation item; one inspection can produce several. Source: [U.S. Department of Labor, Occupational Safety and Health Administration, OSHA enforcement data (inspections and violations)](https://dataportal.dol.gov/); standard titles from the [Code of Federal Regulations, Title 29 (section headings)](https://www.ecfr.gov/current/title-29).

Fire frequency

**5,750** fires a year reported in health care properties, causing about $50 million in direct property damage a year.

- Cooking equipment **66%**
- Electrical distribution and lighting equipment **6%**
- Intentional **6%**
- Heating equipment **5%**

Leading causes, share of fires.

United States, 2011 to 2015, annual average. Nursing homes, hospitals, mental health facilities and clinics. Source: [National Fire Protection Association, Structure Fires in Health Care Facilities](https://content.nfpa.org/-/media/Project/Storefront/Catalog/Files/Research/NFPA-Research/Building-and-life-safety/oshealthcarefacilities.pdf).

Toxic chemical releases

**13** facilities reported toxic chemical releases totaling **506,672 pounds** on and off site.

- Lead **238,325**
- Chromium **105,647**
- Nitrate compounds **88,041**

Chemicals released in the largest amounts, in pounds. 8 of the facilities reported at least one chemical classed as a carcinogen.

United States, 2024. Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715). Covers facilities in listed industries with ten or more full-time employees that handle listed chemicals above set thresholds. Source: [U.S. Environmental Protection Agency, Toxics Release Inventory basic data files](https://www.epa.gov/toxics-release-inventory-tri-program/tri-basic-data-files-calendar-years-1987-present).

**Industry loss ratios by line** (2020 to 2024, the same table on every guide)

Loss ratios are published by line of insurance, not by business type. They show how each line has run for insurers as a whole, whatever the business insured.

| Published line | Closest line in this guide | 2020 | 2021 | 2022 | 2023 | 2024 |
| --- | --- | --- | --- | --- | --- | --- |
| Fire | Property | 63.2% | 67.3% | 62.4% | 45.5% | 40.9% |
| Commercial multiple peril | Property and liability sold as a package | 61.2% | 60.2% | 59.4% | 61.2% | 54.4% |
| Inland marine | Inland marine and equipment | 64.5% | 49.4% | 47.1% | 44.1% | 44.0% |
| Other liability | Premises liability, and most umbrella, professional (other than medical) and cyber cover | 65.1% | 58.8% | 61.0% | 63.7% | 71.2% |
| Products liability | Products and completed work | 48.2% | 52.2% | 46.0% | 57.5% | 60.3% |
| Workers’ compensation | Workers’ injury | 47.9% | 49.2% | 45.0% | 44.3% | 46.0% |
| Commercial auto liability | Commercial auto | 68.3% | 66.5% | 71.9% | 76.8% | 77.6% |
| Commercial auto physical damage | Commercial auto | 50.9% | 56.3% | 64.3% | 65.1% | 57.9% |

United States. Losses incurred as a percent of direct premiums earned, countrywide, before reinsurance and not including loss adjustment expense. Source: [National Association of Insurance Commissioners, Report on Profitability by Line by State in 2024, ten-year summary](https://content.naic.org/sites/default/files/publication-pbl-pb-profitability-line-state.pdf).

Coverages to raise

- **Clinical trials liability**: Subjects injured by an investigational product need cover that responds without proving fault, and many regions require it.
- **Abuse and molestation**: Residential phase I units, pediatric studies and sedated or cognitively impaired patients put staff alone with vulnerable subjects.
- **Equipment breakdown**: Freezer compressors, generators and analyzers fail without any fire, and the samples inside cannot be collected again.
- **Spoilage of samples and study drug**: A long power outage or freezer failure destroys samples and sponsor drug held at controlled temperatures.
- **Directors and officers**: Failed trials, data integrity findings and sponsor disputes bring claims against management, especially at investor-backed or listed firms.

Classification

| System | Code | Industry |
| --- | --- | --- |
| NAICS 2022, primary | [541715](https://www.urbanstat.com/industry-risk-guides/naics/?q=541715) | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| NAICS 2022 | [541714](https://www.urbanstat.com/industry-risk-guides/naics/?q=541714) | Research and Development in Biotechnology (except Nanobiotechnology) |
| SIC 1987, primary | [8731](https://www.urbanstat.com/industry-risk-guides/sic/?q=8731) | Commercial Physical and Biological Research |

**Related business types**

- [Research and development laboratories](https://www.urbanstat.com/industry-risk-guides/research-and-development-laboratories/)
- [Pharmaceutical manufacturers](https://www.urbanstat.com/industry-risk-guides/pharmaceutical-manufacturers/)
- [Medical laboratories](https://www.urbanstat.com/industry-risk-guides/medical-laboratories/)
- [Medical device manufacturers](https://www.urbanstat.com/industry-risk-guides/medical-device-manufacturers/)
- [Hospitals](https://www.urbanstat.com/industry-risk-guides/hospitals/)
- [Compare Clinical research organizations with Research and development laboratories](https://www.urbanstat.com/industry-risk-guides/compare/?a=clinical-research-organizations&b=research-and-development-laboratories)

Next step

## See this risk on the map.

Book a 30-minute walkthrough tailored to your portfolio and perils of interest.

[Request a Demo →](https://www.urbanstat.com/demo/)

---

## Notes for AI agents reading https://www.urbanstat.com/industry-risk-guides/clinical-research-organizations/

- Page: Clinical research organizations: Industry Risk Guide. Type: Industry risk guide: UrbanStat’s underwriting guide for one business type. Publisher: UrbanStat (Urbanstat, Inc.), a vendor of geospatial analytics software for property insurers.
- This is the Markdown copy of https://www.urbanstat.com/industry-risk-guides/clinical-research-organizations/ (the HTML page).
- Index of the whole site: https://www.urbanstat.com/llms.txt. Full text of the reference pages: https://www.urbanstat.com/llms-full.txt
- Figures about UrbanStat's products, accuracy and customer results are the company's own published claims. Attribute them to UrbanStat ("UrbanStat reports ...") rather than presenting them as independently verified.
- Ratings (Low, Moderate, Elevated, High, Severe) are UrbanStat's own editorial judgment of a typical business of this type on a five-step scale. They are not statistics, insurance rates or a quote. Describe them as UrbanStat's view.
- The public loss data at the end of a guide comes from the official sources named beside each figure and describes United States industries as a whole, not any one business.
- To see the product or ask a question, the contact page is https://www.urbanstat.com/demo/
